Clinical trial NCT02662725: Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
Official title: A Multicenter Phase II Study of Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Melanoma
Brain Metastasis
Keywords: melanoma
brain metastasis
stereotactic radiosurgery
Ipilimumab
survival
safety
efficacy
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2016-01-25
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a non-controlled, open label, Phase II Study of ipilimumab combined with a Stereotactic Radiosurgery. The study included an induction phase of four IV infusions of Ipilimumab at 10 mg/kg every 3 weeks associated with a stereotactic radiosurgery performed 3 days before 2nd ipilimumab administration. A Maintenance phase included Ipilimumab, IV, 10 mg/kg once every 12 weeks, starting at week 24, in the absence of PD, unacceptable toxicity or withdrawal of consent or disease progression. The primary objective is the overall survival. The Secondary objectives include safety, ORR, PFS and peripheral blood absolute lymphocyte count (ALC) as a predictive biomarker.


Eligibility criteria: Inclusion Criteria:

1. Willing and able to give written informed consent.
2. Men and women ≥ 18 years of age.
3. Patient eligible to single dose Stereotactic Radiotherapy (Radiosurgery) as per the pluridisciplinary committee.
4. Neurologically asymptomatic or pauci-symptomatic patients. Patients with moderated neurological symptoms without systemic corticosteroids treatment can be included.
5. Less than 4 brain metastasis at the MRI. Brain metastasis should measure less than 3 cm in diameter. At least one brain metastasis \> 5mm.
6. Maximum one prior systemic therapy for metastatic disease is allowed.
7. Prior treatment with INTERFERON in the adjuvant setting is authorized. Prior treatment with anti-CTLA-4 is NOT authorized.
8. ECOG Performance Status 0 or 1
9. Within the last 2 weeks prior to study day 1 the following laboratory parameters, which should be within the ranges specified:

Exclusion Criteria:

1. The patient requires concomitant chronic treatment with systemic corticosteroids or any other immunosuppressive agents 7 days prior to inclusion.
2. Neurological symptoms treated with systemic corticosteroids (whatever the dose of corticoids).
3. The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk such as but not limited to: Cardiac insufficiency (III or IV as per NYHA classification), Renal insufficiency, ongoing infection.
4. Any symptom of concomitant tumour meningitis
5. History of immediate or delayed gadolinium hypersensitivity, or any contraindication to undergo MRI examination (Pacemaker, brain aneurysms clips)
6. Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix (Subjects with a previous malignancy but without evidence of disease for 5 years will be allowed to enter the study)
7. Uncontrolled infectious diseases - requires negative tests for clinically suspected HIV, HBV and HCV. If positive results are not indicative of true active or chronic infection, the subject may enter the study after discussion and agreement between the Investigator and the Medical Monitor.
8. Active autoimmune disease. Autoimmune disease: subjects with a documented history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease are excluded from this study as are subjects with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], Systemic Lupus Erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\]).
9. Subjects with motor neuropathy considered of autoimmune origin (e.g., Guillain Barré Syndrome) are excluded from this study
10. Previous treatment with a CTLA-4 antagonist agent, including treatment in adjuvant setting.
11. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures.
12. Lack of availability for clinical follow-up assessments.
13. For female patients: the patient is pregnant or lactating.
14. Women of childbearing potential: refusal or inability to use effective means of contraception
15. Participation in another clinical trial protocol within 30 days prior to enrolment
16. Persons protected by a legal regime (guardianship, trusteeship)
17. Patients in emergency situations
18. Patients kept in detention

Primary outcomes:
measure: Overall survival rate
timeFrame: until week 96 or death
Secondary outcomes:
measure: All adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria,
timeFrame: through study completion, until week 96
measure: Overall response rate in brain
timeFrame: until week 96 or death
measure: Global overall response rate
timeFrame: until week 96 or death
measure: Disease control rate in brain
timeFrame: until week 96 or death
measure: Global disease control rate
timeFrame: until week 96 or death
measure: Progression free survival
timeFrame: until week 96 or death
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: CHU de Bordeaux
city: Caen
country: France
facility: CHU de Caen
city: Chambray-lès-Tours
country: France
facility: Hôpital Trousseau - CHRU de Tours
city: Clermont - Ferrand
country: France
facility: CHU - Hôpital d'Estaing
city: La Tronche
country: France
facility: Hôpital A. Michallon
city: Lille
country: France
facility: CHRU, Hôpital Claude Huriez
city: Marseille
country: France
facility: AP-HM Hôpital de la Timone
city: Montpellier
country: France
facility: Hôpital Saint Eloi
city: Nantes
country: France
facility: CHU Nantes - Place Alexis Ricordeau
city: Nice
country: France
facility: Hôpital Archet 2
city: Paris
country: France
facility: AP-HP, Hôpital Ambroise Paré
city: Paris
country: France
facility: AP-HP, Hôpital Saint-Louis
city: Pessac
country: France
facility: CHU de Bordeaux
city: Pierre-benite
country: France
facility: Centre hospitalier Lyon Sud
city: Rennes
country: France
facility: Centre Régional de Lutte Contre le Cancer Eugène Marquis
city: Toulouse
country: France
facility: CHU de Toulouse - Larrey
city: Vandoeuvre Les Nancy
country: France
facility: Hôpitaux de Brabois
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: University Hospital, Lille
name: Laurent Mortier, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: